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Intracoronary Injection of In Situ Forming
Alginate Hydrogel Reverses Left Ventricular
Remodeling After Myocardial Infarction in Swine
Jonathan Leor, MD,* Shmuel Tuvia, PHD,† Victor Guetta, MD,* Ferenc Manczur, PHD, DVM,‡
David Castel, DVM,* Udi Willenz, DVM,* Örs Petneha´zy, DVM,§ Natali Landa, PHD,*
Micha S. Feinberg, MD,* Eli Konen, MD, Orly Goitein, MD, Orna Tsur-Gang, PHD,¶
Mazal Shaul, PHD,† Lea Klapper, PHD,† Smadar Cohen, PHD¶
Tel-Hashomer, Jerusalem, and Beer-Sheva, Israel; and Budapest and Kaposvár, Hungary
Objectives This study sought to determine whether alginate biomaterial can be delivered effectively into the infarcted myocar-
dium by intracoronary injection to prevent left ventricular (LV) remodeling early after myocardial infarction (MI).
Background Although injectable biomaterials can improve infarct healing and repair, the feasibility and effectiveness of intra-
coronary injection have not been studied.
Methods We prepared a calcium cross-linked alginate solution that undergoes liquid to gel phase transition after deposi-
tion in infarcted myocardium. Anterior MI was induced in swine by transient balloon occlusion of left anterior
descending coronary artery. At 4 days after MI, either alginate solution (2 or 4 ml) or saline was injected selec-
tively into the infarct-related coronary artery. An additional group (n  19) was treated with incremental volumes
of biomaterial (1, 2, and 4 ml) or 2 ml saline and underwent serial echocardiography studies.
Results Examination of hearts harvested after injection showed that the alginate crossed the infarcted leaky vessels and
was deposited as hydrogel in the infarcted tissue. At 60 days, control swine experienced an increase in left ven-
tricular (LV) diastolic area by 44%, LV systolic area by 45%, and LV mass by 35%. In contrast, intracoronary in-
jection of alginate (2 and 4 ml) prevented and even reversed LV enlargement (p  0.01). Post-mortem analysis
showed that the biomaterial (2 ml) increased scar thickness by 53% compared with control (2.9  0.1 mm vs.
1.9  0.3 mm; p  0.01) and was replaced by myofibroblasts and collagen.
Conclusions Intracoronary injection of alginate biomaterial is feasible, safe, and effective. Our findings suggest a new percu-
taneous intervention to improve infarct repair and prevent adverse remodeling after reperfused MI. (J Am Coll
Cardiol 2009;54:1014–23) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.010t
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meft ventricular (LV) remodeling after myocardial infarction
MI) is often precipitated by early and progressive extracel-
ular matrix (ECM) degradation, infarct expansion, scar
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ccepted June 2, 2009.hinning, and transition to heart failure (1,2). Current
ntiremodeling therapies are clearly limited, because many
entricles continue to enlarge (3,4) and morbidity and
ortality remain high (5).
Recent experiments in small animals have suggested that
irect injection of biomaterials, such as alginate, fibrin,
ollagen, and self-assembling peptide, into the infarct could
ct to internally constrain the myocardium from expanding,
hereby limiting LV remodeling (6–14). We recently
howed that a solution of calcium cross-linked alginate can
e injected via a needle into the infarct, where it undergoes
hase transition into hydrogel (13,14). The alginate hydro-
el implant provides temporary physical support to the
amaged cardiac tissue by replacing some of the functions of
he damaged ECM while preventing adverse cardiac re-
odeling and dysfunction after recent and old MI in the rat13,14). With time, the dissolvable hydrogel gradually
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September 8, 2009:1014–23 Intracoronary Injection of Alginate Biomaterialisappears, and the water-soluble alginate chains are evac-
ated and excreted by the kidneys (15).
Compared with other biomaterials, a major advantage of
he injectable alginate biomaterial solution is nonthrombo-
enicity (16,17). Therefore, we hypothesized that selective
ntracoronary injection of alginate solution will result in
ocalized gelation as scaffold in the infarcted tissue, thereby
reventing adverse LV remodeling. The present study
imed to test this hypothesis in a large animal model of MI.
ethods
he experiments were performed in compliance with animal
elfare regulations of the authors’ institutions conforming
o the “Position of the American Heart Association on
esearch Animal Use,” adopted by the American Heart
ssociation on November 11, 1984.
xperimental groups. Female domestic swine (50 to 60
g) were included in two sets of experiments that were
esigned to determine: 1) the feasibility, safety, and efficacy
f intracoronary injection of alginate biomaterial into nor-
al and infarcted (4 days) heart of swine; and 2) the optimal
olume of alginate biomaterial for intracoronary injection
nd the effect on LV remodeling and function.
njectable alginate solution. The preparation of calcium
ross-linked alginate solution (BL-1040, BiolineRx, Jerusa-
em, Israel) has been previously described (13). In brief, 2
tock solutions were prepared: the first consisted of 2%
eight/volume sodium alginate (VLVG, NovaMatrix,
MC Biopolymers, Drammen, Norway) solution, whereas
he second was composed of 0.6% weight/volume calcium
-gluconate solution. In both cases the materials were
issolved by stirring at room temperature. Each solution was
ltered separately through a sterile 0.2-m membrane into
sterile container under a laminar flow cabinet. Equal
olumes from each stock solution were combined by ho-
ogenization (for several minutes). Biotin-labeled alginate
iomaterial was prepared for detection of the injectable
mplant into the infarcted heart. The biotin-labeled alginate
as cross-linked by calcium ions, as described previously
13).
wine model of MI. An anteroseptal ST-segment eleva-
ion MI was produced in female domestic swine weighing
0 to 60 kg by 60 (first set of experiments for feasibility and
afety) or 90 min (second set of experiments for volume
etermination and remodeling) balloon occlusion in the
id-left anterior descending (LAD) coronary artery (18).
he animals were pre-medicated with aspirin 500 mg,
lopidogrel 300 mg, lopressor 95 mg, and amiodarone 300
g intravenously. Aspirin was continued throughout the
ntire study period and clopidogrel until the day of injec-
ion. Continuous blood pressure, oximetry, and electrocar-
iographic (ECG) changes were monitored throughout the
rocedure. A 12-lead ECG was performed before and after
I and before and after alginate biomaterial delivery. TheT-segment changes in a 12-lead ECG and duration of PR, iRS, QT, and corrected QT
ntervals were measured and an-
lyzed in lead 2.
ntracoronary injection of the
alcium cross-linked alginate
olution. In the first pilot exper-
ment, incremental volumes (6,
, and 10 ml) were injected into
he left coronary system by a
iagnostic 6-F Judkin’s right cor-
nary artery catheter through the
eft main coronary artery of 5
igs. The alginate solution was
njected manually at pressure and
ate similar to contrast media
njection during coronary an-
iography. This pilot experiment
howed that intracoronary injec-
ion of a volume 10 ml of
lginate solution is feasible.
In the next experiment, we
ested the feasibility of delivering
lginate solution into the infarct by intracoronary injection.
ne animal died during anesthesia, before MI induction,
nd thus the final procedure was performed in 8 swine (7
reated with alginate biomaterial and 1 with saline). In this
xperiment, the administration was similar to intracoronary
njection of bone marrow cells (19,20). In brief, 4 days after
I, an over-the-wire angioplasty balloon was inflated at the
cclusion site. Calcium cross-linked alginate solution (2 and
ml) or saline (2 ml) was infused during 3-min balloon
nflation via the guidewire lumen. The balloon was then
eflated and the myocardium reperfused for 3 min. The
ycle was repeated once to deliver the total volume of
lginate solution or saline. After the last infusion, a coronary
ngiogram was performed to assess perfusion in the target
rtery.
In the next experiment, either calcium cross-linked algi-
ate solution (2 or 4 ml) or saline (2 ml) was injected into
he left coronary artery of normal swine. In this experiment,
blood tests for troponin-I levels were obtained before, 12
o 24 h after, and 72 h after injection, after which the
nimals were killed for post-mortem histology.
In the final safety experiment, 2 ml of alginate solution
as injected into 3 animals (3 days after MI), and 6 and 8
l of alginate solution was injected into 2 normal animals.
ntracoronary injections were performed using a multifunc-
ional probing catheter (Multifunctional Probing Catheter,
oston Scientific, Galway, Ireland). Three blood tests for
roponin-I levels were obtained before, 12 to 24 h after, and
2 h after injection. The computed tomography (CT)
ngiography was performed using a 64-slice multidetector
omputed tomography scanner (Brilliance 64, Philips Med-
cal Systems, Cleveland, Ohio) 1 day before and 2 days after
Abbreviations
and Acronyms
CT  computed
tomography
ECG  electrocardiogram/
electrocardiographic
ECM  extracellular matrix
LAD  left anterior
descending
LV  left
ventricle/ventricular
MI  myocardial infarction
MPG  myocardial
perfusion grade
MR  mitral regurgitation
TFG  Thrombolysis In
Myocardial Infarction flow
grade
TIMI  Thrombolysis In
Myocardial Infarctionnjection. The head, chest, abdomen, and pelvis were
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Intracoronary Injection of Alginate Biomaterial September 8, 2009:1014–23canned for possible perfusion defects suggestive of brain or
bdominal parenchymal infarcts or pulmonary emboli.
The second set of experiments was designed to determine
he optimal volume and efficacy of intracoronary injection of
lginate solution into the infarct. Three to 4 days after MI,
ither alginate solution (1, 2, and 4 ml) or saline (2 ml
ontrol) was injected in a single bolus distal to the site of the
AD coronary artery occlusion by a microcatheter.
Angiographic coronary mapping was performed during
he MI procedure, before and 3 min after the injection (day
), and after 60 days. Angiographic images were recorded
nd analyzed in a blinded fashion to assess Thrombolysis In
yocardial Infarction (TIMI) flow grade (TFG) (21), and
yocardial perfusion grade (MPG) (22).
chocardiography to assess LV remodeling and systolic
nd diastolic properties. Echocardiography was per-
ormed as part of a pilot study aimed to determine the
ptimal volume of injectable alginate solution. Echocardi-
graphy was performed under anesthesia, before MI, 3 to 4
ays after MI, and then at 30 and 60 days after MI, using a
hased-array transducer with an ultrasound system (GE
Buckinghamshire, United Kingdom] Logiq book XP,
quipped with S-RS [2–3.6 MHz broadband] phased array
ardiac transducer). Images were recorded and end-diastolic
nd end-systolic frames were selected from standard apical
nd parasternal views. To evaluate diastolic properties,
ulsed-wave Doppler interrogation of mitral inflow was
erformed in a 4-chamber view. Transmitral flow velocities
ere recorded by positioning the sample volume at the
evel of the tip of the mitral valve leaflets. The peak of
he transmitral flow velocity pattern, the E-wave (early
iastolic filling), and the A-wave (late diastolic filling) were
easured. Each variable was quantified by averaging the
easurements obtained from 3 consecutive steady-state
eats.
ost-mortem morphometric and histological analysis.
istological analysis was performed on hearts from all
xperiments. After completion of the in vivo studies, the
earts were arrested with potassium chloride, and rapidly
xcised. A rubber balloon was inserted into the LV and
lled with saline to maintain constant intracavity pressure
uring formalin (10%) fixation. After fixation, the hearts
ere sectioned into 6 to 8 transverse slices (5 mm each)
arallel to the atrioventricular ring. Post-mortem morpho-
etric analysis (scar thickness) was performed on the slice
btained at the level of the papillary muscle. In the CT
ngiography study, analysis was also performed on repre-
entative specimens from the, kidneys, lungs, liver, spleen,
nd brain.
Cubes of tissues from each slice were fixed with 10%
uffered formalin, embedded in paraffin, and sectioned into
-m slices. In the first experiment, the slides were immu-
ostained with avidin-peroxidase (Vector Laboratories,
urlingame, California) to detect the biotin-labeled calcium
ross-linked alginate. In other experiments, serial sections
ere stained with hematoxylin and eosin and immunola-eled with antibodies against -smooth muscle actin iso-
orm (Sigma-Aldrich, St. Louis, Missouri) and von Kossa
taining for calcium (Diagnostic BioSystems, Pleasanton,
alifornia).
tatistical analysis. Statistical analysis was performed with
PSS version 15.01 (SPSS Inc., Chicago, Illinois). All
ariables are expressed as mean  standard error of the
ean. Normality was tested with the Kolmogorov-Smirnov
est. If normally distributed, differences between baseline
nd 8 weeks in the same group were assessed with 2-tailed
aired Student t tests. Percent of change from baseline
chocardiography measurement was calculated for each
nimal as: ([follow-up parameter () baseline parameter]/
aseline parameter)  100. Normality of change was eval-
ated based on the Shapiro-Wilk test, as well as evaluated
raphically by the QQ plots. The difference between means
f groups was compared by analysis of variance test. If
ormality was not found, differences between treatments
ere evaluated by the nonparametric approach of Kruskal-
allis. To test the hypothesis that changes in measures of
LAD
LV apex
Alginate biomaterial 
(white) in infarct (2h 
aer injecon)
A
B
alginate
Figure 1
Macroscopic View of the Infarcted
Heart After Intracoronary Injection of
Calcium Cross-Linked Alginate Solution
(A) Two hours after injection, the alginate hydrogel was identified on the infarct
surface (arrows). (B) Macroscopic view of heart sections revealed hemorrhagic
infarct and in situ deposition of the alginate hydrogel (white areas, arrows)
and consistent distribution of the biomaterial in the granulation tissue. LAD 
left anterior descending; LV  left ventricular.
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September 8, 2009:1014–23 Intracoronary Injection of Alginate BiomaterialV variables over time varied among the experimental
roups, a general linear model 2-way repeated-measures
nalysis of variance was used (23). The model included the
ffects of treatment, time, and treatment-by-time interac-
ion and was followed by a Bonferroni post hoc test. Finally,
linear mix model was applied to analyze the effect of
reatment on diastolic properties over time.
esults
verall, 58 domestic swine were included in 2 sets of
xperiments. After exclusion of animals who either died
uring induction of anesthesia or MI (n  22) or had an
nadequate echocardiography image (1), the final analysis
ncluded 35 swine. The first set of experiments, designed to
etermine feasibility, safety, and efficacy, included 16 swine,
hereas the second set, designed to determine the optimal
olume of injectable alginate implant and its effect on LV
emodeling, included 19 swine.
ntracoronary injection formed hydrogel scaffold in the
nfarcted myocardium. In the experiments designed to
etermine feasibility and efficacy, transient (60-min)
id-LAD coronary artery occlusion produced significant
T-segment elevation MI as assessed by visual inspection
f heart sections: 25% of the LV at the anterior, apical,
eptal, and right ventricular apex. Four days after MI, we
scar - alginate
scar – alginate
X12.5
A
C
Figure 2 Microscopic View of Infarcted Myocardium, 2 h After
Intracoronary Injection of 2 ml Biotin-Labeled Alginate
Upper panels show low-power (12.5) microscopic view of infarcted myocardium 2
(B). (A) Positive brown staining confirms extensive and effective delivery of the alg
hematoxylin. (B) Positive brown staining was absent in saline-treated hearts (12
tion. Positive brown staining of avidin-biotin complex indicates effective delivery of
alginate biomaterial (brown staining) was embedded at the extracellular matrix ofid not observe ischemic ECG changes, conduction
locks, or any type of arrhythmias during and after
njection of alginate solution, and there was no mortality
fter injection.
Two hours after injection, alginate hydrogel could be
dentified (in a few animals) by visual inspection on the
urface of the heart (Fig. 1A). After cross-sectioning,
lginate hydrogel was identified as white palpable areas in
he infarct of all treated animals (Fig. 1B). In animals
reated with biotin-alginate, peroxidase-avidin staining re-
ealed extensive areas of positive brown staining in the
nfarcted tissue (Figs. 2A and 2C), indicating efficient
elivery and deposition of the biomaterial. No positive
rown staining was found in control, saline-treated hearts
Fig. 2B). In 1 animal, the biotin-labeled alginate was also
mbedded at the ECM of the infarct border zone but did
ot affect viable cardiomyocytes (Fig. 2D). There were no
emnants of alginate in either the vascular tree or remote
iable myocardium. Furthermore, we detected no intravas-
ular microthrombi by post-mortem histology.
Together, these findings showed that intracoronary de-
ivery of calcium cross-linked alginate solution is both
easible and safe, and that alginate biomaterial diffuses from
he leaky coronary microvasculature and deposits in the
nfarcted myocardium.
border zone - alginate
scar control
X12.5
B
D
tion or Saline
er intracoronary injection of 2 ml biotin-labeled alginate solution (A) or saline
solution into the infarcted heart. Nuclei of cardiac cells are stained blue by
) High-power (100) view of A. Note typical inflammation after myocardial infarc-
otin-labeled alginate solution into the infarcted heart. (D) In 1 specimen, the
rder zone, and did not affect viable cardiomyocytes (200).Solu
h aft
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.5). (C
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Intracoronary Injection of Alginate Biomaterial September 8, 2009:1014–23o harm with intracoronary injection of alginate bioma-
erial to normal heart. The next experiment was designed
o determine the effect of intracoronary injection of alginate
iomaterial in normal heart. Domestic swine (n  3) were
reated with intracoronary injection of alginate solution (2
r 4 ml) or normal saline (2 ml) delivered into the left main
x100
x200
A
B
Figure 3 Masson Trichrome Staining in Naive Pig
Hearts, 72 h After Alginate (2 ml) Injection
Viable myocardium is stained bright red. Fibrosis should be stained bright blue.
(A) There are no signs of fibrosis in samples from animals treated with intra-
coronary injection of alginate solution (100). Only the connective tissue that
surrounds the artery (tunica adventitia) is stained blue. (B) Higher magnifica-
tion (200) confirmed that intracoronary injection of alginate solution does not
injure the myocardium.
ffect of Various Volumes of Injectable Alginate Biomaterial onhanges () in L Parameters From Baseli e to 30 and 60 Days ATable 1 Effect f Various Volu es of Inj c able Alginate BiomaChanges () in LV Parameters From Baseline to 30 an
Control
(n  4)
1 ml Alginate
Biomaterial
(n  4)
30–3
Days
60–3
Days
30–3
Days
60–3
Days
LV diastolic area 19 6 44 8 14 10 20 17
LV systolic area 25 16 45 24 19 23 1.6 8
LV mass 8 14 35 11 29 16 73 36
Fractional shortening 2 13 5 20 6 14 20 17alues are %.
ANOVA  analysis of variance; Fractional shortening  [(LV diastolic dimension  LV systolic dimensioronary artery. During and after injection, no ischemic
CG changes, conduction blocks, or other types of arrhyth-
ias were observed. Serial troponin-I measurements before,
2 to 24 h after, and 72 h after biomaterial injection) were
ithin normal range. Three days after injection, post-
ortem histological examination of swine hearts and Mas-
on trichrome staining of representative slides showed
ormal myocardium without any evidence of biomaterial
eposition, necrosis, inflammation, or fibrosis at the terri-
ory of injection (Fig. 3). No intravascular thrombi were
etected.
ntracoronary injection of alginate biomaterial does not
roduce remote infarcts. Three MI (day 3) and 2 normal
wine received intracoronary injection of 2 ml of alginate
olution. Two normal swine received 6 and 8 ml of alginate
ithout elevated levels of troponin-I, 12 to 24 and 72 h after
njection. The CT angiography in both MI and normal
wine excluded distal embolization of the biomaterial and
emote infarcts in the brain, lungs, kidneys, spleen, gut, and
iver. These findings were confirmed by post-mortem his-
ology with no evidence of intravascular thrombi or damage
o the heart, lungs, kidneys, liver, spleen, lymph nodes, and
one marrow.
ntracoronary injection of alginate biomaterial prevents
V remodeling after MI. The second set of experiments
90-min coronary artery occlusion) was designed to deter-
ine the optimal volume of alginate implant that improves
V remodeling after MI. The changes in echocardiography
ariables from baseline (day 3 after MI before injection) to 30
nd 60 days after MI are presented in Table 1 and Figure 4. At
0 days, control swine experienced a significant increase in
V diastolic area (44  8%; p  0.01), LV systolic area (45 
4%; p  0.18), and LV mass (35  11%; p  0.02) from
aseline. In contrast, intracoronary injection of alginate
iomaterial prevented and even reversed LV enlargement.
or example, after 60 days, intracoronary injection of 2 ml
f biomaterial reversed LV diastolic and systolic dilation
p  0.01 compared with control). Furthermore, 2 ml of
lginate injection attenuated the increase in LV mass,
ompared with control (2  8% vs. 35  11%; p  0.02).
imilarly, injection of 4 ml alginate (n  4) reversed
nlargement of LV (p  0.01 compared with control).
Il on
Days After MI
2 ml Alginate
Biomaterial
(n  7)
4 ml Alginate
Biomaterial
(n  4) p Value (ANOVA)
30–3
ays
60–3
Days
30–3
Days
60–3
Days
30–3
Days
60–3
Days
 4 1 4 1 2 6 4 0.11 0.006
 4 13 4 2.4 1 9 10 0.35 0.02
 7 2 8 16 14 11 18 0.28 0.049
 10 31 20 3 6 15 18 0.81 0.81fter Mteria
d 60

D
1
1
7
10on)/LV diastolic dimension]; LV  left ventricular; MI  myocardial infarction.
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September 8, 2009:1014–23 Intracoronary Injection of Alginate Biomaterialnimals treated with 1 ml (n  4) alginate biomaterial
xperienced a mild favorable effect on LV diastolic and
ystolic area (p  0.32 and p  0.13, compared with
ontrol). Thus, the protective effects on LV remodeling
ere more prominent in animals treated with 2 and 4 ml of
lginate biomaterial (Fig. 4).
During a 60-day follow-up, satisfactory transmitral
oppler echocardiography measurements were obtained in
nimals treated by 2 (n  7), 1 (n  2), and 4 ml (n  2) of
lginate or saline (n  3). During follow-up, control animals
aintained a trend for a restrictive LV filling pattern with an
ncreased E/A ratio (Fig. 5). In contrast, this trend was
ecreased in animals treated with 2 ml of alginate (p 0.02 for
reatment over time interaction) (Fig. 5).
ffect on coronary artery flow and myocardial perfusion.
igh-quality angiography for TFG and MPG analyses was
vailable from 17 of the 19 MI swine included in the volume
Change in LV diastolic area
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Figure 4 Effect of Intracoronary Injection of Various Volumes
of Alginate on LV Dilation 30 and 60 Days After MI
Comparison of the therapeutic effects of intracoronary delivery of 1, 2, and 4
ml of alginate solution or saline (2 ml) into recent (4-day-old) scar. All volumes
of alginate attenuate or prevent left ventriculat (LV) diastolic (A) and systolic
(B) dilation compared with control. Relative change was calculated as ([30 or
60 day measure – 3 day measure]/3 day measure)  100. Individual values
and mean (SEM). The p values are for treatment effect versus control by
repeated-measures analysis of variance (ANOVA) and Bonferroni post hoc test
adjusted for multiple comparisons. MI  myocardial infarction.etermination study. The TFG and MPG, immediatelyfter alginate biomaterial delivery and 60 days later, were
ssessed in a blinded manner. Intracoronary injection (1 and
ml) did not affect coronary flow and myocardial perfusion as
ssessed by TFG and MPG (Fig. 6). Only 2 swine (1 control
nd 1 from the 4 ml biomaterial group) had impaired
erfusion after intracoronary injection. Thus, injection of 1
nd 2 ml of alginate solution does not affect coronary blood
ow in either epicardial coronary arteries or in myocardial
icrocirculation.
njectable alginate biomaterial increase scar thickness. Post-
ortem morphometric analysis of the heart sections at the
evel of the papillary muscles was performed 2 months after
iomaterial injection (Fig. 7). No remnants of alginate or
nfarct calcifications were found by both echocardiography
nd von Kossa calcium staining. Alginate biomaterial (2 ml)
ncreased scar thickness by 53% compared with control (2.9 0.1
m vs. 1.9  0.3 mm; p  0.01), and anterior wall
hickness by 34% (9.1  0.5 mm vs. 6.8  0.9 mm; p 
.03). Histological examination showed accumulation of
yofibroblasts at the scar tissue without remnants of the
iomaterial (Fig. 8A). Examination of control heart sections
reated with saline showed positive staining for -smooth
uscle actin predominantly on the vessel walls (Fig. 8B).
iscussion
he present study shows that intracoronary injection of
lginate biomaterial is feasible and effective in preventing
dverse cardiac remodeling in swine. Our model mimics
he scenario of ST-segment elevation MI with coronary
eperfusion, and the injection of alginate biomaterial 4
ays after MI with 60 days of follow-up is relevant to the
ealing and repair phase after MI. After intracoronary
njection, the alginate solution disseminates through the
eaky vessels into the infarct and undergoes phase tran-
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Figure 5 Diastolic Properties Were Improved in Alginate
Biomaterial-Treated Animals by Doppler Echocardiography
Diastolic properties were evaluated by serial Doppler echocardiography tests.
During a 60-day follow-up, control animals maintained a trend for restrictive LV
filling pattern presented by increased E/A ratio. In contrast, the E/A ratio
decreased in alginate-treated animals (p  0.02 for treatment over time inter-
action by a linear mix model). Abbreviations as in Figure 4.
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CM in the infarcted tissue and the scaffolding effect of
he alginate hydrogel provide physical support to the
nfarcted tissue, enhance healing, and prevent LV dila-
Saline (control) 2 ml
3 min 60 d 3 min 60 d
0
1
2
3
4
TIMI 
TIMI 
TFG MPG
n
u
m
b
er
 o
f 
an
im
al
s
3 min 60 d 3 min 60 d
0
1
2
3
4
TIMI 3
TFG MPG
alginate 2ml
n
u
m
b
er
 o
f 
an
im
al
s
Figure 6 Alginate Solution (1 and 2 ml) Does Not Affect TFG a
MPG  myocardial perfusion grade; TFG  Thrombolysis In Myocardial Infarction fl
Scar thickness
al
gi
na
te
 2
 m
l (
n=
7)
Co
nt
ro
l (
n=
4)
0
5
10 p<0.01
m
m
alginate
LV LV
Figure 7 Alginate Implant Increases Scar Thickness by Post-M
Representative sections of heart treated with alginate (upper left panel) or saline
that injection of alginate solution (2 ml) increases scar thickness (arrows) as wellion. The implant was gradually replaced by myofibro-
lasts and connective tissue. An increased number of
yofibroblasts in the scar is considered a marker of
mproved healing (24), and is found after biomaterial or
3 min 60 d 3 min 60 d
0
1
2
3
4
TIMI 3
TFG MPG
alginate 1 ml
n
u
m
b
er
 o
f 
an
im
al
s
3 min 60 d 3 min 60 d
0
1
2
3
4
TIMI 3
TIMI 2
TIMI 1
TFG MPG
alginate 4 ml
n
u
m
b
er
 o
f 
an
im
al
s
PG 3 Min and 60 Days After Intracoronary Injection
de; TIMI  Thrombolysis In Myocardial Infarction.
Anterior wall  thickness
al
gi
na
te
 2
 m
l (
n=
7)
Co
nt
ro
l (
n=
4)
0
5
10 p=0.03
m
m
saline
LV LV
Morphometry, 60 Days After MI
r right panel). Morphometry shows
terior wall thickness (lower panels). Abbreviations as in Figure 4.3
2
nd M
ow graortem
(uppe
as an
c
t
g
I
t
e
M
i
(
r
o
a
d
(
m
s
i
o
l
m
i
(
f
p
M
i
w
g
I
s
p
t
d
o
d
g
t
m
t
b
i
i
p
a
i
c
r
d
k
a
w
i
o
b
t
b
s
i
e
o
S
d
a
c
t
i
a
r
M
i
i
i
a
e
1021JACC Vol. 54, No. 11, 2009 Leor et al.
September 8, 2009:1014–23 Intracoronary Injection of Alginate Biomaterialell therapy (13,25–27). Thus, injectable alginate bioma-
erial supports local infarct healing while limiting more
eneralized myocardial remodeling.
njectable biomaterials for heart repair. Progressive
hinning and enlargement of the infarct zone (infarct
xpansion) are events that occur during the first days after
I (2). Injectable biomaterials can reduce wall stress by
ncreasing scar thickness and stabilizing chamber size
6,8,9,12,28). By thickening the scar, wall stress is
educed (Laplace law) and the degree of outward motion
f the infarct that occurs during systole (dyskinesis) is
lso reduced. This effect is analogous to an external
evice that constrains the myocardium from expanding
29). Injectable biomaterial could also repair or prevent
echanical complications after MI. A recent preliminary
tudy showed that injection of polyvinyl alcohol polymer
nto inferior MI in 6 sheep resulted in decreased severity
f acute mitral regurgitation (MR) compared with base-
ine (30). Using injectable alginate solution in a dog
A. alginate-treated scar
B. saline-treated scar
Figure 8
Representative Micrographs of Infarcted
Hearts After Immunostaining for -SMA,
60 Days After Either Alginate or Saline Injection
(A) Examination of the scar tissue showed that the alginate-treated scar is
populated with numerous myofibroblasts that were stained positive for -SMA.
(B) Examination of control sections treated with saline showed positive stain-
ing for -SMA predominantly on the vessel walls. SMA  smooth muscle actin.odel of inferior MI (n  30) showed that the severity of tschemic MR can be reduced during a 6-month follow-up
31). This new approach offers a percutaneous alternative
or relieving ischemic MR by correcting papillary muscle
osition and relieving the tethering that causes ischemic
R. Finally, injectable biomaterial can also create an
mproved environment for myocardial repair (6,10), as
ell as a platform for controlled delivery of therapeutic
enes and proteins (32–35).
ntracoronary administration of alginate biomaterial
olution. Ideally, injectable biomaterial for myocardial re-
air should possess the following characteristics: 1) gels at
he infarct site only; 2) rapid, controllable gelation without
etrimental effects on myocardial function and remote
rgans; 3) sufficient tissue-bulking properties to support
amaged myocardium; 4) bio-erodible; 5) nonimmuno-
enic; and 6) nonthrombogenic and can be injected selec-
ively into the infarct-related artery.
Alginate, a polysaccharide found in brown seaweed,
eets many of these criteria. It has been used extensively in
he food, pharmaceutical, and medical device industries. It is
iocompatible, and its cross-linked hydrogel form is similar
n structure to that of ECM (17). The injectable biomaterial
s delivered into the infarcted tissue through damaged,
ermeable vessels in the infarct zone. In contrast, when
lginate solution was delivered into normal heart, with
ntact coronary vessels, it did not penetrate into the myo-
ardium or into remote organs with intact vessels. The
emnants of the biomaterial that did not deposit in the heart
issolved in the bloodstream and were excreted by the
idneys (15). To partially mimic the clinical scenario,
nimals were treated with aspirin throughout the study and
ith clopidogrel up to the day of alginate injection. No
ntravascular thrombi were detected by post-mortem histol-
gy in infarcted or in normal hearts. This may be explained
y the nonthrombogenic properties of alginate (16), and by
he fact that physiologic concentrations of calcium in the
lood are insufficient for intravascular conversion of alginate
olution into gel. In the present study, we show that
ntracoronary injection of 2 ml of alginate solution is more
ffective than 1 ml, showing similar beneficial effects to that
f 4 ml in preventing LV remodeling.
tudy limitations. First, the functional experiments were
esigned to determine the optimal injectable volume of
lginate implant. Thus, our functional findings should be
onsidered preliminary and interpreted with caution. Fur-
hermore, because of the relatively small number of animals
n each group, differences between some variables did not
chieve statistical significance. However, our findings were
ecently confirmed by another group using a dog model of
I (31). Second, the absence of cardiac magnetic resonance
maging data is a weakness. Cardiac magnetic resonance
maging is rapidly becoming the standard reference modal-
ty for assessment of LV dimensions, global LV function,
nd myocardial mass in pre-clinical research. Third, the
ffect of injectable alginate biomaterial on diastolic dysfunc-
ion is uncertain and needs to be substantiated by hemody-
n
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resent study, Doppler echocardiography measurements
ere used for estimating diastolic properties and suggest a
ossible benefit from the injection of biomaterial into a
ecent infarct. This finding is in accord with the improved
V remodeling and systolic function in biomaterial-treated
nimals, as well as our previous experiments in rats (13).
owever, a bias may have been created because Doppler
easurements were not available in all swine because of
echnical difficulties.
Finally, our pig model mimics ST-segment elevation MI
ith early reperfusion, a scenario that is generally associated
ith improved infarct healing and LV remodeling (36). It
ould be practical to test the efficacy of our approach in a
arge animal model of permanent coronary occlusion with
xtensive infarct. Nevertheless, based on our work in a rat
odel of extensive MI (13), we predict that this approach
ould be effective in a large infarct.
onclusions
ur experiments provide a novel catheter-based strategy of
njectable, bioresorbable alginate implant to improve cardiac
emodeling after MI. Biomaterial injection has several
dvantages over current approaches to treatment of LV
emodeling after MI. The injectable implant increases scar
hickness and provides physical support for improved heal-
ng and repair. The ability to deliver biomaterial into the
nfarct by intracoronary injection can revolutionize patient
reatment after MI and could prevent mechanical compli-
ations, heart failure, and death.
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